Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

18.85
-0.2462-1.29%
Volume:195.52K
Turnover:3.68M
Market Cap:2.14B
PE:-7.58
High:18.98
Open:18.88
Low:18.62
Close:19.10
52wk High:30.06
52wk Low:13.49
Shares:113.58M
Float Shares:108.26M
Volume Ratio:1.24
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:4.08
PE(LYR):-7.75

Loading ...

Immunome Director Isaac Barchas Disposes of 201,050 Common Shares Worth $4.4 Million

Reuters
·
Jul 03

Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile

TIPRANKS
·
Jun 30

Immunome Chief Medical Officer Robert Lechleider Disposes of 55,000 Common Shares Worth $1.09 Million

Reuters
·
Jun 30

Immunome’s New Radiopharma Trial Puts IMNM on Early Oncology Watchlists

TIPRANKS
·
Jun 19

Immunome CFO Max Rosett disposes of 60,000 common shares worth $1.09 million

Reuters
·
Jun 18

Immunome shareholders reaffirm board, auditor and pay policies

TIPRANKS
·
Jun 13

Immunome shareholders elect three Class III directors at annual meeting

Reuters
·
Jun 13

Immunome (IMNM) Receives a Buy from Wedbush

TIPRANKS
·
Jun 13

Immunome Price Target Maintained With a $31.00/Share by Wedbush

Dow Jones
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)

TIPRANKS
·
Jun 12

Craig-Hallum Sticks to Its Buy Rating for Immunome (IMNM)

TIPRANKS
·
Jun 11

Immunome doses first patient in Phase 1 trial of IM-1617 solid-tumor ADC

Reuters
·
Jun 11

Immunome - Plans Ind Submission for IM-1340 in Mid-2026 and IM-1335 in Late 2026

THOMSON REUTERS
·
Jun 11

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients With Advanced Solid Tumors

THOMSON REUTERS
·
Jun 11

Immunome director Jean Jacques Bienaime sells USD 203,820 of common shares

Reuters
·
Jun 10

Immunome grants 353,000 inducement stock options to new hires at USD 20.78 strike price

Reuters
·
Jun 05

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

GlobeNewswire
·
Jun 03

Wedbush Remains a Buy on Immunome (IMNM)

TIPRANKS
·
Jun 01

Lake Street Remains a Buy on Immunome (IMNM)

TIPRANKS
·
Jun 01

Immunome announces Ringside trial met primary, secondary endpoints

TIPRANKS
·
May 31